Raymond James Financial Services Advisors Inc. Acquires 15,038 Shares of Teva Pharmaceutical Industries Limited (TEVA)

Raymond James Financial Services Advisors Inc. raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 10.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,633 shares of the company’s stock after acquiring an additional 15,038 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Teva Pharmaceutical Industries Limited were worth $5,303,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Chou Associates Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 134.9% during the 2nd quarter. Chou Associates Management Inc. now owns 505,000 shares of the company’s stock worth $16,839,000 after purchasing an additional 290,000 shares during the last quarter. TT International boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.8% during the 2nd quarter. TT International now owns 179,573 shares of the company’s stock worth $5,965,000 after purchasing an additional 4,827 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 62.5% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,775,753 shares of the company’s stock worth $191,861,000 after purchasing an additional 2,221,695 shares during the last quarter. Caxton Associates LP boosted its stake in shares of Teva Pharmaceutical Industries Limited by 6.6% during the 2nd quarter. Caxton Associates LP now owns 13,000 shares of the company’s stock worth $432,000 after purchasing an additional 800 shares during the last quarter. Finally, Earnest Partners LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 39.5% during the 2nd quarter. Earnest Partners LLC now owns 2,992,743 shares of the company’s stock worth $99,419,000 after purchasing an additional 847,451 shares during the last quarter. Hedge funds and other institutional investors own 56.75% of the company’s stock.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 4.3875% during mid-day trading on Friday, reaching $14.4853. 9,842,284 shares of the company’s stock traded hands. Teva Pharmaceutical Industries Limited has a 12 month low of $14.30 and a 12 month high of $44.49. The stock’s market capitalization is $14.72 billion. The firm’s 50-day moving average price is $16.76 and its 200 day moving average price is $26.28.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 earnings per share. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.25 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were paid a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 2.24%. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

WARNING: “Raymond James Financial Services Advisors Inc. Acquires 15,038 Shares of Teva Pharmaceutical Industries Limited (TEVA)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://sportsperspectives.com/2017/10/13/raymond-james-financial-services-advisors-inc-acquires-15038-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Several research firms have issued reports on TEVA. Jefferies Group LLC reaffirmed a “hold” rating and set a $26.00 price target (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. ValuEngine raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Piper Jaffray Companies set a $23.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research note on Friday, October 6th. Deutsche Bank AG reaffirmed a “buy” rating and set a $28.00 price target (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Five investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $27.63.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply